Maintain MDT at 2.5% portfolio cap; Hold into FY27 Q1 catalyst with pre-committed scale-in triggers
The neutral analyst lands the calibrated middle: Hold with 2.5% cap preserved, mechanical re-engagement triggers at $90.50–$91.50 and $88.50–$89.00 with confirmed technical conditions, pre-committed catalyst framework, and avoidance of alpha bleed from over-trimming into overbought readings on defensive compounders. The position is already sub-3.5% per 8/12 lesson, so additional trimming compounds alpha-bleed risk without asymmetric benefit. All three analysts agree $94+ is not the entry.
| Position | Action |
|---|---|
| Current position is at 2.5% cap (already sub-3.5% per 8/12 lesson) | No action required—position is appropriately sized |
| First scale-in trigger at $90.50–$91.50 | Add 50% of intended position size |
| Second scale-in trigger at $88.50–$89.00 | Add remaining 50% of intended position size |
Medtronic offers a compelling bull case anchored in revenue growth reacceleration to 8.4% in FY26, an attractive forward P/E of 14.7x with EPS nearly doubling to $6.41 as one-time charges normalize, imminent Dividend King status (49 consecutive years of hikes), and constructive technical/macro tailwinds supporting further upside.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 90.52 | bullish |
| close_50_sma | 83.71 | bullish |
| close_200_sma | 88.59 | bullish |
| rsi | 75.05 | bearish |
| macd | 2.60 | bullish |
| macd_signal | 2.15 | bullish |
| macd_histogram | 0.45 | bullish |
| bollinger_upper_band | 94.23 | neutral |
| vwma | 88.85 | bullish |
| atr | 2.16 | neutral |
Support: 94.71 · 96.05 · 96.97 · 100 · 101 · 103.05 · 103.76 | Resistance: 92.09 · 90.76 · 88.59 · 87.82 · 83.71 · 78.97
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: $88.50–$89.00 (200 SMA + VWMA confluence) with volume capitulation >12M on decline
Then: Add remaining 50% of intended add
Affera approval closes the cardiac ablation narrative gap, positioning MDT competitively against Boston Scientific's Farapulse and J&J's Varipulse
↩ rebuts: “Bear argument that MDT is a cardiac ablation laggard andDexcom/Abbott/Insulet are crushing MDT in diabetes”
· concedes: $88M hernia mesh verdict is real and material but not thesis-breaking (0.24% of revenue, 1.83% of net income); RSI at 75 is technically overbought, though it's a normal mid-trend pause not a reversal signal; Light volume (4.65M vs 14.5M breakout session) is normal for follow-through days after institutional initiation; Goodwill-heavy balance sheet with negative tangible book value is a real accounting fact, though irrelevant for cash-flow analysis; Restructuring charges recurring at $300-500M annually are real costs, though strategic and should improve future margins; Tax rate volatility from 16.6% to 21.2% is a one-time TTM distortion that should stabilize going forward; 50 SMA gap of 12% above price is wide but closing organically as the 50 SMA catches up
MDT is a trap at current levels: the stock trades at overbought extremes (RSI 75.05, upper Bollinger Band) heading into binary earnings with a 25.2x trailing P/E that requires a near-doubling of EPS to $6.41 to justify, the revenue "reacceleration" is FX-inflated with operating margin actually compressing, litigation risk is precedent-setting, and the technical setup shows distribution signals — recommending SELL/UNDERWEIGHT with pullback targets of $90.50, $88.50-$89, and $83.71.
· concedes: The trend is real but exhausted on near-term metrics; Diversification premium is real but already priced in (beta of 0.57); Dividend King designation will be a catalyst when the hike actually happens; Diversification does provide some recession hedge
→ vs conservative: RSI at 75 in strong trend with MACD bullish cross and higher lows is trend strength signal, not reversal; trimming on overbought readings in base breakout gifting back 10-15% of upside
→ vs conservative: Low volume at $94 is consolidation, not distribution; prior 14.5M volume day and 5.3% seven-session rally confirmed breakout; volume confirms reversals/breakdowns not healthy uptrends
→ vs conservative: Waiting for $90.50 pullback on reaccelerating growth at 14.7x forward multiple is anchoring to technicals while ignoring peer multiple gap; not a 'hold' setup, a mispricing setup
→ vs conservative: Pre-earnings trim ignores BofA bullish call, Affera approval catalyst, Dividend King proximity, and 6.1/10 sentiment with zero euphoria pricing; asymmetric opportunity exists on beat-and-raise
→ vs conservative: $88M verdict on $36B revenue base = $0.03 EPS exposure, noise; even tripling for clustering risk = $0.09, absorbed by 27% EPS expansion in Q3 alone
→ vs conservative: Macro concerns ignore 35-40% non-US revenue as FX tailwind and defensive dividend payer outperformance in higher-for-longer/soft-landing scenario
→ vs neutral: Intellectually defensible HOLD is strategically lazy; dominant fundamental story of 8% reaccelerator at 14.7x with catalysts deserves conviction sizing, not dribble-in pullback approach
Medtronic has staged a significant technical breakout after four months of basing, reclaiming the 200-day SMA and closing decisively above all three key moving averages. Momentum is bullish with MACD in a fresh bullish crossover and expanding histogram, but RSI at 75.05 indicates overbought conditions and today's close at the upper Bollinger Band (94.23) with a $94.71 intraday high that failed to hold suggests a potential mean-reversion pullback is likely. Volume of 4.65M on today's session is notably lighter than the 10M+ and 20M+ sessions seen during the May capitulation and July 28 breakout, creating a negative divergence. Key support levels are the 200 SMA ($88.59), Bollinger middle band ($87.82), and 50 SMA ($83.71), while resistance sits at today's high ($94.71) extending toward the $96-$103 zone. The actionable recommendation is to HOLD existing positions without adding, and wait for a pullback to the $90.50-$91.50 zone (10 EMA area) or $88.50-$88.85 zone (200 SMA/VWMA confluence) before entering new positions, with stops placed near $87.80.
Market Cap
$120.5 B
Share Price (implied)
~$94.13
52-Week High
$106.33
52-Week Low
$73.31
50-Day MA
$83.62
200-Day MA
$89.76
P/E (TTM)
25.2x
Forward P/E
14.7x
PEG Ratio
1.8
P/B
2.44x
Dividend Yield
3.13%
Beta
0.57
Diluted Shares
1.288B
Revenue (FY2026)
$36.36B
Revenue YoY Growth (FY2026)
+8.4%
Gross Profit (FY2026)
$23.64B
EBITDA (FY2026)
$9.81B
Net Income (FY2026)
$4.80B
Diluted EPS (TTM)
$3.73
Forward EPS
$6.41
Gross Margin
65.0%
Operating Margin
22.0%
Net Margin
13.2%
ROE
9.84%
ROA
4.92%
Total Assets
$93.0B
Total Equity
$49.5B
Long-Term Debt
$26.1B
Net Debt
$26.0B
Cash & ST Investments
$9.22B
Goodwill
$42.6B
Other Intangibles
$10.1B
Goodwill + Intangibles
$52.7B
Debt/Equity
58.2%
Current Ratio
2.13x
Tangible Book Value
-$3.27B
Net Debt / EBITDA
~2.6x
Operating Cash Flow (FY2026)
$7.33B
CapEx (FY2026)
$1.90B
Free Cash Flow (FY2026)
$5.43B
FCF Yield
~4.5%
Dividends Paid (FY2026)
$3.64B
Buybacks (FY2026)
$1.04B
R&D Spend (FY2026)
$2.87B
R&D as % of Revenue
7.9%
SG&A (FY2026)
$11.78B
SG&A as % of Revenue
32.4%
Tax Rate (FY2026)
21.2%
Restructuring Charges (FY2026)
~$362M
Inventory
$5.95B
Receivables
$6.64B
Strengths
Concerns
Medtronic is a diversified medical device giant (market cap $120.5B) with FY2026 revenue of $36.36B growing 8.4% - the strongest organic growth in recent years, driven by Hugo robotic-assisted surgery, Symplicity Spyral RDN, and diabetes platforms. The forward P/E of 14.7x (based on $6.41 consensus EPS vs. TTM $3.73 depressed by restructuring and tax) is reasonable for a BBB+/A-rated franchise with stable 65% gross margins and strong FCF of $5.43B supporting a 3.13% dividend yield. Key risks include high goodwill ($42.6B), recurring restructuring charges, and intensifying competition in diabetes and cardiac ablation.
Macro: Fed policy: 85% probability of no rate cuts in 2026 (Polymarket, little changed -0.5pp week-over-week); most FOMC participants support a hold; Treasury expanding long-bond buybacks to pressure long yields down. US soft landing base case with 8% recession probability (down 0.5pp WoW). Japan recession risk at 31% (up 3pp). Oil +36%, Strait of Hormuz closed—energy shock risk rising with partial offset from Exxon/SLB restarting 15 Venezuela rigs. US equity indexes ended higher on FOMC hold signal and Treasury buyback expansion; tech leading losses in Asia, energy leading globally. Dollar weakness is a tailwind for MDT's ~35-40% non-US revenue.